[Anxiety and Substance Abuse Disorders-Focus on Alcohol and Cannabis]

Overview

Journal Nervenarzt

Specialty Neurology

Date 2023 Jun 21

PMID 37341771

Authors

Sabine Hellwig

Katharina Domschke

Affiliations

Soon will be listed here.

Abstract

Anxiety disorders are frequent, with a 12-month prevalence of 14%, tend to be chronic, and display a high comorbidity with substance abuse disorders. Anxiety and substance abuse disorders are associated with a pronounced individual as well as socioeconomic burden. This article reviews the epidemiological, etiological, and clinical aspects of the dual diagnosis of anxiety and substance abuse disorders, with a particular focus on alcohol and cannabis. The treatment comprises nonpharmacological strategies, mainly cognitive behavioral therapy combined with elements of motivational interviewing (MI) and pharmacological management with antidepressants; however, the use of selective serotonin reuptake inhibitors (SSRI)/serotonin and noradrenaline reuptake inhibitors (SNRI) is not unreservedly recommended. The use of gabapentinoids requires careful risk-benefit consideration because of their potential for abuse and dependence in substance abuse disorders. Benzodiazepines are reserved exclusively for crisis management. Rapid diagnosis and treatment initiation targeting both disorders are essential for successful treatment of comorbid anxiety and substance abuse disorders.

References

Olesen J, Gustavsson A, Svensson M, Wittchen H, Jonsson B . The economic cost of brain disorders in Europe. Eur J Neurol. 2011; 19(1):155-62. DOI: 10.1111/j.1468-1331.2011.03590.x. View

Wittchen H, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B . The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol. 2011; 21(9):655-79. DOI: 10.1016/j.euroneuro.2011.07.018. View

Bandelow B, Michaelis S . Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015; 17(3):327-35. PMC: 4610617. View

Xiong P, Liu M, Liu B, Hall B . Trends in the incidence and DALYs of anxiety disorders at the global, regional, and national levels: Estimates from the Global Burden of Disease Study 2019. J Affect Disord. 2021; 297:83-93. DOI: 10.1016/j.jad.2021.10.022. View

Grant B, Stinson F, Dawson D, Chou S, Dufour M, Compton W . Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2004; 61(8):807-16. DOI: 10.1001/archpsyc.61.8.807. View

Smith J, Book S . Anxiety and Substance Use Disorders: A Review. Psychiatr Times. 2010; 25(10):19-23. PMC: 2904966. View

Grant B, Goldstein R, Saha T, Chou S, Jung J, Zhang H . Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015; 72(8):757-66. PMC: 5240584. DOI: 10.1001/jamapsychiatry.2015.0584. View

Grant B, Saha T, Ruan W, Goldstein R, Chou S, Jung J . Epidemiology of DSM-5 Drug Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions-III. JAMA Psychiatry. 2015; 73(1):39-47. PMC: 5062605. DOI: 10.1001/jamapsychiatry.2015.2132. View

Xue S, Husain M, Zhao H, Ravindran A . Cannabis Use and Prospective Long-Term Association with Anxiety: A Systematic Review and Meta-Analysis of Longitudinal Studies: Usage du cannabis et association prospective à long terme avec l'anxiété: une revue systématique et une méta-analyse.... Can J Psychiatry. 2020; 66(2):126-138. PMC: 7918873. DOI: 10.1177/0706743720952251. View

10.

Hines L, Freeman T, Gage S, Zammit S, Hickman M, Cannon M . Association of High-Potency Cannabis Use With Mental Health and Substance Use in Adolescence. JAMA Psychiatry. 2020; 77(10):1044-1051. PMC: 7254445. DOI: 10.1001/jamapsychiatry.2020.1035. View

11.

Onaemo V, Fawehinmi T, DArcy C . Comorbid Cannabis Use Disorder with Major Depression and Generalized Anxiety Disorder: A Systematic Review with Meta-analysis of Nationally Representative Epidemiological Surveys. J Affect Disord. 2020; 281:467-475. DOI: 10.1016/j.jad.2020.12.043. View

12.

Kozak K, Smith P, Lowe D, Weinberger A, Cooper Z, Rabin R . A systematic review and meta-analysis of sex differences in cannabis use disorder amongst people with comorbid mental illness. Am J Drug Alcohol Abuse. 2021; 47(5):535-547. PMC: 9144491. DOI: 10.1080/00952990.2021.1946071. View

13.

Some N, Wells S, Felsky D, Hamilton H, Ali S, Elton-Marshall T . Self-reported mental health during the COVID-19 pandemic and its association with alcohol and cannabis use: a latent class analysis. BMC Psychiatry. 2022; 22(1):306. PMC: 9055215. DOI: 10.1186/s12888-022-03917-z. View

14.

Bruce S, Yonkers K, Otto M, Eisen J, Weisberg R, Pagano M . Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005; 162(6):1179-87. PMC: 3272761. DOI: 10.1176/appi.ajp.162.6.1179. View

15.

Hornig C, McNally R . Panic disorder and suicide attempt. A reanalysis of data from the Epidemiologic Catchment Area study. Br J Psychiatry. 1995; 167(1):76-9. DOI: 10.1192/bjp.167.1.76. View

16.

Meier S, Petersen L, Mattheisen M, Mors O, Mortensen P, Laursen T . Secondary depression in severe anxiety disorders: a population-based cohort study in Denmark. Lancet Psychiatry. 2015; 2(6):515-23. PMC: 5087327. DOI: 10.1016/S2215-0366(15)00092-9. View

17.

Puddephatt J, Irizar P, Jones A, Gage S, Goodwin L . Associations of common mental disorder with alcohol use in the adult general population: a systematic review and meta-analysis. Addiction. 2021; 117(6):1543-1572. PMC: 9300028. DOI: 10.1111/add.15735. View

18.

Vorspan F, Mehtelli W, Dupuy G, Bloch V, Lepine J . Anxiety and substance use disorders: co-occurrence and clinical issues. Curr Psychiatry Rep. 2015; 17(2):4. DOI: 10.1007/s11920-014-0544-y. View

19.

Hill K, Gold M, Nemeroff C, McDonald W, Grzenda A, Widge A . Risks and Benefits of Cannabis and Cannabinoids in Psychiatry. Am J Psychiatry. 2021; 179(2):98-109. DOI: 10.1176/appi.ajp.2021.21030320. View

20.

Volkow N, Wang G, Fowler J, Tomasi D, Baler R . Food and drug reward: overlapping circuits in human obesity and addiction. Curr Top Behav Neurosci. 2011; 11:1-24. DOI: 10.1007/7854_2011_169. View